Symmetric Dimethyl Arginine (SDMA) Recombinant Rabbit mAb (S-2129-14)

Symmetric Dimethylarginine (SDMA) is a metabolic product of the post-translational modification of arginine residues in proteins, a process catalyzed by protein arginine methyltransferases (PRMTs). Unlike its isomer, Asymmetric Dimethylarginine (ADMA), the two methyl groups in SDMA are attached symmetrically to the nitrogen atoms of the arginine's guanidino group. This critical structural difference results in a major distinction in their biological functions: ADMA is a potent inhibitor of endothelial nitric oxide synthase (NOS), impeding the production of nitric oxide (NO), whereas SDMA has a very weak direct inhibitory effect on NOS. However, SDMA is not physiologically insignificant; it can indirectly interfere with the cellular uptake of the NOS substrate L-arginine by competing for the cationic amino acid transporters (y+ transport system) on the cell membrane, thereby influencing NO synthesis. In recent years, the clinical importance of SDMA has grown significantly, particularly in nephrology, where it has been recognized as an excellent biomarker that is earlier and more sensitive than creatinine in detecting a decline in the glomerular filtration rate (GFR). This is because it is almost exclusively excreted by the kidneys and is unaffected by common confounding factors such as muscle mass, age, gender, or diet. Furthermore, elevated SDMA levels have also been associated with cardiovascular disease, inflammation, and poor prognosis in various clinical conditions, making it a valuable tool for comprehensive risk assessment.